Novonesis (NZM) AI Stock Analysis

Novonesis

(Frankfurt:NZM)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Organic growth and upgraded guidanceBroad-based organic growth and upgraded full-year guidance indicate sustained customer demand across Novonesis’s biosolutions portfolio. Volume-led expansion, pricing, and sales synergies should support revenue progression while the diversified end-market exposure reduces reliance on a single application area.

Negative Factors

Inconsistent bottom-line profitabilityA TTM net loss alongside healthy operating margins indicates that reported earnings are less consistent than the underlying operating performance. Profit volatility can reduce confidence in repeatable earnings conversion and make future returns more sensitive to non-operating or one-time effects.

Novonesis (NZM) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 32.19B
Dividend Yield: 0.22%
Average Volume (3M): 14
Price to Earnings (P/E): 44.2
Beta (1Y): 0.36
Revenue Growth: 4.86%
EPS Growth: 11.74%
Country: Germany
Employees: 11,641
Sector: Basic Materials
Sector Strength: 61
Industry: Chemicals - Specialty

Novonesis Business Overview & Revenue Model

Company Description

Novozymes A/S is a global biotechnology firm that specializes in the creation and distribution of industrial enzymes, microorganisms, and probiotics. Its operational footprint spans across Europe, the Middle East, Africa, North America, Latin America...

Novonesis Earnings Call Summary

Earnings Call Date:Aug 18, 2026(Q2-2026)|% Change Since:12.24%|Next Earnings Date:Nov 06, 2024

Earnings Call SentimentPositive

The call presented strong, broad-based organic growth, margin expansion, robust cash generation and clear capital allocation actions (EUR 1bn buyback, bolt‑on M&A, capacity investments). These positives were balanced by notable headwinds — currency effects, country exits, a softer Human Health outlook, one-off inventory timing and a temporary elevation in CapEx and operating costs. On balance the company appears to be executing well and is confident in sustainable demand and returns, but investors should monitor H2 effects from tariff reimbursements, the normalization of the Q1 inventory benefit and the near-term impact of elevated CapEx.

Positive Updates

Strong top-line growth

Organic sales grew 8% in H1 2026 (9% in Q2). Reported euro sales rose 7% in H1 and 10% in Q2. Pricing contributed ~2 percentage points and sales synergies ~1 percentage point to growth.

Negative Updates

Currency headwinds

Currency movements were a material drag: currencies provided a ~4 percentage-point headwind to organic growth in H1 (and ~1 percentage point in Q2), partially offsetting margin gains.

Company Guidance

Novonesis raised its 2026 organic sales guidance to 7–8%, expecting growth to be mainly volume-driven and supported by roughly 1 percentage point each from pricing and sales synergies while including close to a 1 pp drag from exiting certain countries; the outlook also factors a minor H2 headwind from U.S. tariff reimbursements (up to ~40 bps), a softer Human Health H2 and high Q3 comparables. Management now expects adjusted EBITDA margin at the higher end of the 37–38% range (~38%) and net debt/EBITDA of ~1.8x at year‑end, with 2026 CapEx stepped up to 12–14% of sales (normalizing to high single‑digits by 2030). They announced a EUR 1bn buyback through 2029, an interim dividend of DKK 2.35, and reiterated the target to double adjusted ROIC (ex‑goodwill) to 16% by 2030; H1 metrics included operating cash flow EUR 523.3m, free cash flow before acquisitions EUR 307.6m and adjusted EPS (ex PPA) EUR 1.09 (+9% y/y).

Novonesis Peers Comparison

Overall Rating

UnderperformOutperform

Sector (61)

Financial Indicators

DE:NZM against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SHW	69Neutral	$80.35B	30.29	63.49%	0.96%	7.03%	5.95%
EMN	65Neutral	$7.61B	11.73	10.63%	5.05%	0.40%	-6.58%
ESI	62Neutral	$8.31B	40.55	7.39%	0.93%	39.62%	-14.83%
PPG	62Neutral	$26.40B	16.98	19.05%	2.40%	6.39%	27.29%
Sector *	61Neutral	$10.43B	7.12	-0.05%	2.87%	2.86%	-36.73%
SCL	61Neutral	$1.58B	366.37	0.36%	2.27%	10.02%	-90.50%

* Basic Materials Sector Average

Performance Comparison

DE:NZM and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:NZM	Novonesis A/S - Adr	61.00	10.54	20.89%
EMN	Eastman Chemical Company	66.53	11.40	20.67%
PPG	Ppg Industries, Inc.	119.52	26.98	29.16%
SHW	Sherwin-Williams	332.61	-9.78	-2.86%
SCL	Stepan Company	69.61	28.35	68.72%
ESI	Element Solutions	34.27	7.41	27.57%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Novonesis AI Stock Analysis